Table 1

Characteristics of the study population (n = 72) at baseline visit of the study (mean ± SEM)
Parameter L-Carnitine (n = 38) Placebo (n = 34)
gender male 20 (52.6%) 23 (67.6%)
female 18 (47.4%) 11 (32.4%)
mean age 64.4 ± 1.67 64.4 ± 1.65
Karnofsky performance status 76.8 ± 1.87 80.0 ± 2.16
Nutritional Status
normal BMI (kg/m²) 28.0 ± 1.01 30.1 ± 0.84
baseline visit BMI (kg/m²) 24.7 ± 0.65 24.9 ± 0.89
Phase angle (°) 4.4 ± 0.16 4.4 ± 0.17
Weight loss* present 34 (89.5%) 31 (91.2%)
absent 4 (10.5%) 3 (8.8%)
meanweight loss (kg)* 11.4 ± 1.28 12.3 ± 1.56
Nutritional support none 20 (52.6%) 21 (61.8%)
oral 14 (36.8%) 9 (26.5%)
Parenteral nutrition 4 (10.5%) 4 (11.7%)
ECM/BCM index ** 1.5 ± 0.11 1.4 ± 0
Cell percentage (%) 41.8 ± 1.22 42.70 ± 1.21
chemotherapy (n) 35 (92%) 30 (88%)
Laboratory values
L-Carnitine level (μmol/l) 25.3 ± 2.29 24. 8 ± 2.11
Albumine (g/l) 33.8 ± 1.09 33.7 ± 1.20
CRP (mg/l) 31.3 ± 6.55 45.5 ± 10.39
Leucocytes (Gpt/l) 8.3 ± 0.83 6.9 ± 0.46
CA 19–9 (U/ml) 14,095 ± 32,572 18,345 ± 35,950

No statistically significant differences were observed between L-Carnitine and placebo group.

*weight loss during the last 6 month.

**ECM/BCM-Index, Extra-Cellular-Mass/Body-Cell-Mass-Index.

Kraft et al.

Kraft et al. Nutrition Journal 2012 11:52   doi:10.1186/1475-2891-11-52

Open Data